Video

Dr. Mikhael on Remaining Challenges in High-Risk Multiple Myeloma

Joseph Mikhael, MD, discusses remaining challenges in high-risk multiple myeloma.

Joseph Mikhael, MD, professor, Applied Cancer Research and Drug Discovery Division, Translational Genomics Research Institute (TGen), an affiliate of City of Hope Cancer Center, chief medical officer, International Myeloma Foundation, discusses remaining challenges in high-risk multiple myeloma.

Within the past decade, the average survival of patients with multiple myeloma has significantly improved compared with historic rates, says Mikhael. However, survival has not been improved to the same degree in patients with high-risk disease.

Additionally, patients with extramedullary disease, who can also be considered high risk, remain a challenging patient population to treat, Mikhael explains. Extramedullary disease presents de novo outside of the medullary space. Moreover, these patients can be challenging to image, measure, and treat as they may have heavy disease burden. Future research efforts should aim to identify a treatment strategy for patients with extramedullary disease, concludes Mikhael.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity